Guerbet Expands Pediatric MRI Contrast Use
Imaging agent manufacturer Guerbet has received an expanded pediatric indication for gadopiclenol, a next-generation MRI contrast agent. The label expansion reflects a push for more age-specific imaging solutions and greater scrutiny of contrast agent safety. This development is relevant for imaging centers that serve pediatric populations.
- The recent FDA approval for gadopiclenol, marketed as Elucirem™ by Guerbet, now includes pediatric patients from birth to two years of age. This macrocyclic agent is administered at half the gadolinium dose of standard contrast agents, a significant factor for vulnerable populations like infants and patients requiring multiple scans. - Gadopiclenol has the highest relaxivity and stability of all gadolinium-based contrast agents (GBCAs) currently on the market, allowing for effective lesion visualization at a lower dose. Clinical trials have shown that a 0.05 mmol/kg dose of gadopiclenol is noninferior to a 0.1 mmol/kg dose of the standard agent gadobutrol for body and CNS imaging. - This label expansion addresses long-standing concerns about gadolinium retention in the body, particularly in the brain, which has been a subject of FDA warnings since 2017. While no definitive adverse health effects have been linked to retention in patients with normal kidney function, the FDA recommends using the lowest effective dose. - The outpatient imaging sector, a key market for mobile providers, is experiencing a significant shift away from hospitals, driven by lower-cost, patient-centric models. However, this sector also faces pressures from declining reimbursements from both Medicare and commercial payers, who are increasingly adopting site-neutral payment policies. - Despite reimbursement challenges, the demand for advanced outpatient imaging like MRI and CT is projected to grow. This trend puts a premium on operational efficiency, creating an opening for technologies and agents that can increase patient throughput and diagnostic confidence. - The FDA has cleared hundreds of AI algorithms for radiology, with medical imaging being the largest target for AI medical device approvals. These tools assist with workflow triage, image interpretation, and even automated reporting, aiming to increase speed and accuracy in diagnostics. - Guerbet and Bracco Imaging have a worldwide collaboration for the manufacturing, research, and development of gadopiclenol, which they commercialize independently under the brand names Elucirem™ and VUEWAY™, respectively. Gadopiclenol was first approved by the FDA for adults and children aged 2 and older in September 2022.
